Bright Minds Biosciences Inc.
DRUG
Classifica tra le azioni
#12700
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Prezzo delle azioni
$52.67
Capitalizzazione di mercato
$519.58M
Variazione (1 giorno)
4.43%
Variazione (1 anno)
-13.15%
Paese
US
Scambia Bright Minds Biosciences Inc. (DRUG)
Categoria
Healthcare
Storico del prezzo dell'azione per Bright Minds Biosciences Inc. (DRUG)
Prezzo di chiusura più alto: $53.83 il 2026-10-01
Prezzo di chiusura più basso: $33.56 il 2021-02-01
Prezzo di chiusura più basso: $33.56 il 2021-02-01
Storico del prezzo dell'azione di Bright Minds Biosciences Inc. dal 2021 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -8.79% |
| 2025 | 105.52% |
| 2024 | 2,581.73% |
| 2023 | -68.72% |
| 2022 | -73.66% |
| 2021 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
